Vistagen Therapeutics Inc. – Filings and Transcripts

NASDAQ: VTGN
Share price (6/30/26): $0.23
Market cap (6/30/26): $9.273 million

Warning: Large portions of this site require JavaScript enabled in order to function properly. Please make sure JavaScript is enabled in your browser.

Please let us know at support@bamsec.com if you have any questions or concerns.

Search in Documents

Key Exhibits

External Links

Financials Filter

ended 03/31/26 FY 2026

ended 12/31/25 Q3

ended 09/30/25 Q2

ended 06/30/25 Q1

ended 03/31/25 FY 2025

Prospectuses and Registrations Filter

Prospectus supplement for primary offering

Registration of securities for employees

Shelf registration

Prospectus supplement for primary offering

Prospectus supplement for primary offering

Ownership Filter

Angelov Angel S

Angelov Angel S

TCG Crossover GP II, LLC

Prince Joshua S.

News Filter

Announces Topline and Post-Hoc Data From PALISADE-4 Phase 3 Public Speaking Challenge Trial of Fasedienol for the Acute Treatment of Social Anxiety Disorder

Change in Directors, Officers or Compensation

Reports Fiscal Year 2026 Financial Results and Provides Corporate Update

Achieves Minimum ICH Safety Exposure Recommendations Across Clinical Program for Fasedienol for the Acute Treatment of Social Anxiety Disorder

Appoints Angel S. Angelov, MD, MBA, as Chief Medical Officer

Proxies Filter

Additional info about upcoming vote

Definitive proxy

Additional info about upcoming vote

Definitive proxy

Definitive proxy

Other Filter

Notice of effectiveness

Correspondence with the SEC

Letter from the SEC

Notice of effectiveness

Correspondence with the SEC